Ovarian tissue cryopreservation for fertility preservation before hematopoietic stem cell transplantation in patients with sickle cell disease: safety, ovarian function follow-up, and results of ovarian tissue transplantation.
Fertility preservation
Hematopoietic stem cell transplantation
Ovarian function follow-up
Ovarian tissue cryopreservation
Ovarian tissue transplantation
Sickle cell disease
Journal
Journal of assisted reproduction and genetics
ISSN: 1573-7330
Titre abrégé: J Assist Reprod Genet
Pays: Netherlands
ID NLM: 9206495
Informations de publication
Date de publication:
15 Feb 2024
15 Feb 2024
Historique:
received:
23
11
2023
accepted:
02
02
2024
medline:
15
2
2024
pubmed:
15
2
2024
entrez:
15
2
2024
Statut:
aheadofprint
Résumé
To describe the experience of performing ovarian tissue cryopreservation (OTC) before hematopoietic stem cell transplantation (HSCT), among girls/women with severe sickle cell disease (SCD)(SS or S/β This retrospective study included 75 patients (girls/women) with SCD who have had OTC before myeloablative conditioning regimen (MAC) for HSCT. Characteristics of patients and data on OTC, ovarian status follow-up, and results of ovarian tissue transplantation (OTT) were collected in medical records. At OTC, the median (IQR 25-75; range) age of the patients was 9.6 (6.9-14.1; 3.6-28.3) years, 56/75 were prepubertal, and no SCD or surgery-related complications occurred. The median follow-up post-HSCT was > 9 years. At the last follow-up, among prepubertal patients at HSCT, 26/56 were ≥ 15 years old and presented with a premature ovarian insufficiency (POI), except 2, including the patient who had received an OTT to induce puberty. Eight were 13-15 years old and presented for POI. The remaining 22 patients were under 13. Among the 19 patients who were menarche at HSCT, 2 died 6 months post-HSCT and we do not have ovarian function follow-up for the other 2 patients. All the remaining patients (n = 15) had POI. Five patients had OTT. All had a return of ovarian function. One patient gave birth to a healthy baby. OTC is a safe fertility preservation technique and could be offered before MAC independent of the patient's age.
Identifiants
pubmed: 38358434
doi: 10.1007/s10815-024-03054-4
pii: 10.1007/s10815-024-03054-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Bernaudin F, Dalle JH, Bories D, de Latour RP, Robin M, Bertrand Y, et al. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. Haematologica. 2020;105:91–101.
doi: 10.3324/haematol.2018.213207
pubmed: 31097628
pmcid: 6939536
Socié G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003;101:3373–85.
doi: 10.1182/blood-2002-07-2231
pubmed: 12511420
Nickel RS, Maher JY, Hsieh MH, Davis MF, Hsieh MM, Pecker LH. Fertility after curative therapy for sickle cell disease: a comprehensive review to guide care. J Clin Med. 2022;11:2318.
doi: 10.3390/jcm11092318
pubmed: 35566443
pmcid: 9105328
Meacham LR, George S, Veludhandi A, Pruett MC, Haight AE, Arnold SR, et al. Female reproductive health outcomes after hematopoietic cell transplantation for sickle cell disease: is reduced intensity better than myeloablative conditioning? Transplant Cell Ther. 2023;29:531.
doi: 10.1016/j.jtct.2023.05.004
Dovey S, Krishnamurti L, Sanfilippo J, Gunawardena S, Mclendon P, Campbell M, et al. Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report. J Assist Reprod Genet. 2012;29:265–9.
doi: 10.1007/s10815-011-9698-2
pubmed: 22219083
pmcid: 3288130
Pecker LH, Maher JY, Law JY, Beach MC, Lanzkron S, Christianson MS. Risks associated with fertility preservation for women with sickle cell anemia. Fertil Steril. 2018;110:720–31.
doi: 10.1016/j.fertnstert.2018.05.016
pubmed: 30196969
Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112:1022–33.
doi: 10.1016/j.fertnstert.2019.09.013
Poirot CJ, Martelli H, Genestie C, Golmard JL, Valteau-Couanet D, Helardot P, et al. Feasibility of ovarian tissue cryopreservation for prepubertal females with cancer. Pediatr Blood Cancer. 2007;49:74–8.
doi: 10.1002/pbc.21027
pubmed: 16977608
Armstrong AG, Kimler BF, Smith BM, Woodruff TK, Pavone ME, Duncan FE. Ovarian tissue cryopreservation in young females through the Oncofertility Consortium’s National Physicians Cooperative. Future Oncol. 2018;14:363–78.
doi: 10.2217/fon-2017-0410
pubmed: 29345507
pmcid: 5827816
Dolmans MM, Hossay C, Nguyen TYT, Poirot C. Fertility preservation: how to preserve ovarian function in children, adolescents and adults. J Clin Med. 2021;10:5247.
doi: 10.3390/jcm10225247
pubmed: 34830528
pmcid: 8621487
Bedrick BS, Kohn TP, Pecker LH, Christianson MS. Fertility preservation for pediatric patients with hemoglobinopathies: multidisciplinary counseling needed to optimize outcomes. Front Endocrinol (Lausanne). 2022;13: 985525.
doi: 10.3389/fendo.2022.985525
pubmed: 36353243
pmcid: 9638952
Poirot C, Vacher-Lavenu MC, Helardot P, Guibert J, Brugières L, Jouannet P. Human ovarian tissue cryopreservation: indications and feasibility. Hum Reprod. 2002;17:1447–52.
doi: 10.1093/humrep/17.6.1447
pubmed: 12042259
Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31:926–37.
doi: 10.1093/humrep/dew027
pubmed: 27008889
Poirot C, Fortin A, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, et al. Impact of cancer chemotherapy before ovarian cortex cryopreservation on ovarian tissue transplantation. Hum Reprod. 2019;34:1083–94.
doi: 10.1093/humrep/dez047
pubmed: 31116405
Frange P, Peffault de Latour R, Arnaud C, Boddaert N, Oualha M, Avettand-Fenoel V, et al. Adenoviral infection presenting as an isolated central nervous system disease without detectable viremia in two children after stem cell transplantation. J Clin Microbiol. 2011;49:2361–4.
doi: 10.1128/JCM.00080-11
pubmed: 21490187
pmcid: 3122733
Poirot C, Abirached F, Prades M, Coussieu C, Bernaudin F, Piver P. Induction of puberty by autograft of cryopreserved ovarian tissue. Lancet. 2012;379:588.
doi: 10.1016/S0140-6736(11)61781-9
pubmed: 22325664
Imbert R, Moffa F, Tsepelidis S, Simon P, Delbaere A, Devreker F, et al. Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis. Hum Reprod. 2014;29:1931–40.
doi: 10.1093/humrep/deu158
pubmed: 24958067
Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16:263–72.
doi: 10.1016/j.bbmt.2009.10.005
pubmed: 19822218
Smith-Whitley K. Reproductive issues in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2014;2014:418–24.
doi: 10.1182/asheducation-2014.1.418
pubmed: 25696888
Jadoul P, Guilmain A, Squifflet J, Luyckx M, Votino R, Wyns C, et al. Efficacy of ovarian tissue cryopreservation for fertility preservation: lessons learned from 545 cases. Hum Reprod. 2017;32:1046–54.
doi: 10.1093/humrep/dex040
pubmed: 28333228
Kristensen SG, Wakimoto Y, Colmorn LB, Dueholm M, Pors SE, Macklon KT, et al. Use of cryopreserved ovarian tissue in the Danish fertility preservation cohort. Fertil Steril. 2021;116:1098–106.
doi: 10.1016/j.fertnstert.2021.05.096
pubmed: 34130800
Ernst E, Kjærsgaard M, Birkebæk NH, Clausen N, Andersen CY. Case report: stimulation of puberty in a girl with chemo- and radiation therapy induced ovarian failure by transplantation of a small part of her frozen/thawed ovarian tissue. Eur J Cancer. 2013;49:911–4.
doi: 10.1016/j.ejca.2012.09.028
pubmed: 23084082
Dolmans MM, von Wolff M, Poirot C, Diaz-Garcia C, Cacciottola L, Boissel N, et al. Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers. Fertil Steril. 2021;115:1102–15.
doi: 10.1016/j.fertnstert.2021.03.008
pubmed: 33933173
Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Restoration of ovarian function after orthotopic (intraovarian and periovarian) transplantation of cryopreserved ovarian tissue in a woman treated by bone marrow transplantation for sickle cell anaemia: case report. Hum Reprod. 2006;21:183–8.
doi: 10.1093/humrep/dei268
pubmed: 16126712
Roux C, Amiot C, Agnani G, Aubard Y, Rohrlich PS, Piver P. Live birth after ovarian tissue autograft in a patient with sickle cell disease treated by allogeneic bone marrow transplantation. Fertil Steril. 2010;93(2413):e15–9.
Demeestere I, Simon P, Dedeken L, Moffa F, Tsépélidis S, Brachet C, et al. Life birth after autograft of ovarian tissue cryopreserved during childhood. Hum Reprod. 2015;30:2107–9.
doi: 10.1093/humrep/dev128
pubmed: 26062556
Rives N, Courbière B, Almont T, Kassab D, Berger C, Grynberg M, et al. What should be done in terms of fertility preservation for patients with cancer? The French 2021 guidelines. Eur J Cancer. 2021;173:146–66.
doi: 10.1016/j.ejca.2022.05.013